Technology | Clinical Decision Support | April 30, 2018

Point of Care Decision Support Releases New Version of Anticoagulation Software

Clinical decision support software version 2.0 adds new features, improves performance and supports CMS reimbursement requirements

Point of Care Decision Support Releases New Version of Anticoagulation Software

Image courtesy of Point of Care Decision Support


April 30, 2018 — Point of Care Decision Support (PCDS) announced the release of a new version 2.0 of their anticoagulation clinical decision support (CDS) software. The application was developed with leading clinical thrombosis experts to specifically address the new and complex challenges of managing both warfarin and non-vitamin K antagonist oral anticoagulants (NOACs). It enables healthcare provider teams to deliver consistent, measurable and evidence-based quality of care for patients on anticoagulants.

Key benefits to healthcare practitioners that electronically document care for patients on an oral anticoagulant therapy include:

  • Central patient dashboard that allows them to understand the patient's history and plan in less than 60 seconds;
  • Automatic dosage calculations using validated nomograms to assist in medication management;
  • Integration with validated survey instruments such as CHA2DS2-VASc, HAS-BLED and HEMORR2HAGES;
  • Full patient plan of care instructions available to print, providing a customized and relevant shared patient/clinician experience;
  • Electronic medical record (EMR)-agnostic integration with bidirectional flow of patient data that dramatically decreases data entry; and
  • Enhanced reporting options that meet Centers for Medicare and Medicaid Services (CMS)/Medicare Access and CHIP Reauthorization Act (MACRA) "high activity" improvement requirements.

PCDS demonstrated AC 2.0 at the AC Forum Boot Camp for physicians, nurses and pharmacists that work with patients on oral anticoagulant therapies, April 23-24 in Austin, Texas.

For more information: www.ptofcare.com

 


Related Content

News | Antiplatelet and Anticoagulation Therapies

August 28, 2023 — Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not ...

Home August 28, 2023
Home
News | Antiplatelet and Anticoagulation Therapies

March 24, 2023 — According to the U.S. Food and Drug Administration (FDA), Ascend Laboratories LLC is voluntarily ...

Home March 24, 2023
Home
News | Antiplatelet and Anticoagulation Therapies

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

Home November 14, 2022
Home
News | Antiplatelet and Anticoagulation Therapies

November 17, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline ...

Home November 17, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE ...

Home November 09, 2021
Home
News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
Subscribe Now